Composites based on heparin and MIL-101(Fe): The drug releasing depot for anticoagulant therapy and advanced medical nanofabrication

Vladimir V. Vinogradov, Andrey S. Drozdov, Leila R. Mingabudinova, Emiliya M. Shabanova, Nina O. Kolchina, Elizaveta I. Anastasova, Alina A. Markova, Alexander A. Shtil, Valentin A. Milichko, Galina L. Starova, Rafaella L.M. Precker, Alexandr V. Vinogradov, Evamarie Hey-Hawkins, Evgeny A. Pidko

    Research output: Contribution to journalArticleScientificpeer-review

    11 Citations (Scopus)

    Abstract

    We describe the synthesis and properties of a new composite material based on heparin and MIL-101(Fe) metal-organic framework. The intrinsic instability of MIL-101(Fe) towards hydrolysis enables binding of heparin molecules to the framework structure as is evidenced by DFT calculations and adsorption experiments. The de novo formed heparin-MOF composites showed good biocompatibility in in vitro and demonstrated pronounced anticoagulant activity. The specific interaction between the bioactive molecule and the carrier is critical for the selective degradation of the complex in the body fluids and for the enhanced activity. Hep-MIL-101(Fe) composite could serve as a drug-releasing depot for nanofabrication and to introduce anticoagulant activity to medical devices and biocoatings. Addition of Hep-MIL-101(Fe) to a sol-gel derived thrombolytic matrix allowed the combination of anticoagulant and thrombolytic activities in a single hybrid nanomaterial that could be applied as a bioactive nanocoating for PTFE vein implants.

    Original languageEnglish
    Pages (from-to)2450-2459
    Number of pages10
    JournalJournal of Materials Chemistry B
    Volume6
    Issue number16
    DOIs
    Publication statusPublished - 2018

    Fingerprint Dive into the research topics of 'Composites based on heparin and MIL-101(Fe): The drug releasing depot for anticoagulant therapy and advanced medical nanofabrication'. Together they form a unique fingerprint.

    Cite this